Merck KGAA to acquire Silence Therapeutics for billions
German pharmaceutical and chemical group Merck KGAA has entered into an agreement to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion, equivalent to SEK 12.9 billion.
By Finwire
Advertisement
The offer amounts to $20 per American depositary receipt, equivalent to a premium of 82 per cent compared with the volume-weighted average price over the past 30 days. This is stated in a press release.
The acquisition will be financed with new loans and is expected to be completed during the first quarter of 2027, subject to the necessary approvals.
BREAKING